Allergan continues Viberzi push with online IBS-D awareness tool

IBSDonTract.com

Allergan is working to grow its market share for IBS-D therapy Viberzi. And to that end, it’s rolling out a new tool that it hopes will help grow the market.

Earlier this week, the company launched IBSDonTract.com, an online resource for the 15 million U.S. sufferers of the malady. Included on the website is information on identifying symptoms, managing the condition and speaking with a doctor about IBS-D, Allergan said.

The company is hoping the new site will help patients--often held back by “embarrassment or uncertainty about symptoms”--see a doctor about the condition, and, in turn, understand their options, Gavin Corcoran, Allergan’s CMO, said in a statement.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

One of those options is, of course, Viberzi, the treatment that won FDA approval the very same day as Valeant rival Xifaxan. Unlike Allergan, though--whose contender was held up by DEA scheduling--Valeant got right to work rolling out its product, along with a DTC effort featuring the divisive, pink “gut guy.”

Allergan struck back not long ago, though, with a spokescharacter of its own. This spring, a redhead in a flesh-colored unitard--Irritabelle--took center stage to help hawk Viberzi, interrupting and annoying patients the same way the malady can.

And so far, the Dublin drugmaker’s work on the launch is paying off, Chief Commercial Officer Bill Meury recently told shareholders. Since Viberzi hit the market at the end of 2015, more than 8,000 physicians have prescribed the therapy, with about 65% of the base falling into the “repeat prescriber” category. And the company has seen “a nice boost to scripts” since the DTC campaign took off in April, Meury said.

- read Allergan's release

Special Report: Top 10 animated characters in pharma marketing - Xifaxan Gut Guy - Valeant

Related Articles:
Vexing IBS-D spokescharacter 'Irritabelle' headlines Allergan's Viberzi ad push
Love it or hate it, Valeant's wobbly pink 'Gut Guy' for Xifaxan is getting noticed​
Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push
Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA
Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi
GI dealmaking pays off for Valeant, Actavis with same-day FDA nods in IBS

Read more on

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.